Ground News

Don't Just Read the News, Understand It.

Cure SMA image

News from Cure SMA

Stay current with all the latest and breaking news from Cure SMA. Compare headlines and media bias behind news outlets on stories breaking today.

In total, 3 have been published by Cure SMA which Ground News has aggregated in the past 3 months.

Ground News rates Cure SMA’s media bias as unknown. . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Cure SMA’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Cure SMA

Where is Cure SMA located?Cure SMA's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Cure SMA News

Novartis Gene Therapies Releases Spring SMA Community Update Letter

United States · United States

Novartis Gene Therapies Releases Spring SMA Community Update Letter

Novartis Gene Therapies recently released an update on their continued collaboration with the SMA community through events, advisory boards, clinical insights, and ongoing efforts to center patient, family, and community voices in their work. Read the full community update letter here. "As winter turns to spring, we want to recognize that we have had an amazing time connecting with you at the Summit of Strength events so far this year. We are e…Read Article

New form of SMA treatment Evrysdi may give patients 'freedom'

United States · United States

New form of SMA treatment Evrysdi may give patients 'freedom'

A tablet formulation of Evrysdi (risdiplam) for spinal muscular atrophy (SMA) recently approved in the U.S. is designed to give patients a new option, a Genentech official said. “Evrysdi is the only oral, non-invasive disease-modifying SMA treatment, and the new tablet formulation may provide greater freedom and independence for people with SMA, thanks to simplified dose administration,” said Gregory Rippon, MD, vice president and chief medical …See the Story

FDA Grants Priority Review BLA for Spinal Muscular Atrophy Drug, Apitegromab

FDA · United States

FDA Grants Priority Review BLA for Spinal Muscular Atrophy Drug, Apitegromab

A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.See the Story

You've scrolled to the bottom of the feed, there are no more stories.